| Name | Title | Contact Details |
|---|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
At Medical Equipment Doctor we partner up with you to keep your budget and costs in check by providing pre-owned medical equipment sales, serviceand rental for all your facility needs. Contact us today.
Biocodex is a San Bruno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gala Therapeutics is a medical devices company developing therapies to improve survival, quality of life, and outcomes for patients with pulmonary diseases.
Zenabis is a significant Licensed Producer of medical and recreational cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, British Columbia; and Stellarton, Nova Scotia.